Tirzepatide (Mounjaro, Zepbound) is an FDA-approved dual GIP/GLP-1 receptor agonist used for type 2 diabetes and chronic weight management
Many patients believe these medications are equivalent to FDA-approved products because they produce similar weight loss or glycemic improvements
Oral semaglutide (Rybelsus) is available for diabetes management but is not currently licensed for weight management in the UK
Contra-Indications: Though compounded semaglutide might be unsuitable for patients suffering from underlying medical conditions, pregnant women suffering from particular health conditions should strictly avoid it, and be most careful while contemplating fasting
These results were attributed not just to improved glycemic control, but to anti-inflammatory effects on arterial walls, reduced plaque formation, and enhanced endothelial function
"It is very expensive," said Jeffrey Beckham, the state budget director in Connecticut, where Medicaid coverage of the drugs for weight loss may be scrapped entirely